Maprotiline HCl Rx
Generic Name and Formulations:
Maprotiline HCl 25mg, 50mg, 75mg; tabs.
Indications for Maprotiline HCl:
Treatment of depressive illness in patients with depressive neurosis (dysthymic disorder) and manic-depressive illness, depressed type (major depressive disorder). Relief of anxiety associated with depression.
Mild-moderate depression: initially 75mg daily; maintain for 2 weeks, may increase in 25mg increments as required and tolerated. Usual max 150mg daily. Severely depressed or hospitalized: initially 100–150mg daily; may increase to max 225mg daily if necessary. Maintenance: use lowest effective dose; may be reduced to 75–150mg daily; adjust as needed. Elderly (>60yrs): initially 25mg daily; maintenance therapy: 50–75mg daily.
<18yrs: not recommended.
Seizure disorder. Within 14 days of MAOIs. Acute phase of MI.
History of MI. Cardiovascular disease. Discontinue prior to elective surgery. Increased intraocular pressure. Urinary retention. Narrow-angle glaucoma. Hyperthyroidism. Monitor leukocyte and differential counts in patients who develop fever and sore throat; discontinue if evidence of pathological neutrophil depression. Write ℞ for smallest amount needed. Pregnancy (Cat.B). Nursing mothers.
See Contraindications. Potentiates CNS depression with concomitant alcohol, barbiturates, other CNS depressants. Additive atropine-like effects with anticholinergics, sympathomimetics. Avoid concomitant electroshock therapy. Potential for cardiovascular toxicity with thyroid drugs. May antagonize guanethidine. Concomitant phenothiazines, or rapid tapering of benzodiazepines: increased risk of seizures. May be potentiated by hepatic enzyme inhibitors (eg, cimetidine, fluoxetine). May be antagonized by hepatic enzyme inducers (eg, barbiturates, phenytoin).
Drowsiness, dry mouth, nervousness, dizziness, constipation, blurred vision, tremor, GI upset, anxiety, insomnia, weakness, fatigue, headache, agitation.
Formerly known under the brand name Ludiomil.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Despite Promising Trial Results, Skeptics Raise Red Flags About Anlotinib's Efficacy in Heavily Treated NSCLC
- Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed
- Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma
- Prostate Cancer Drug Resistance Mediated by Epigenetic Changes
- Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML